MUC1 and COVID-19: Although values of all three biomarkers were only available for a minority of our study population, our results showed that the combination of MR-proADM, KL-6 and IL-6 improved accuracy for outcome prediction and may be valuable in the clinical management of hospitalized COVID-19 patients.